Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gossamer Bio Inc (GOSS)

Gossamer Bio Inc (GOSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 833,242
  • Shares Outstanding, K 231,456
  • Annual Sales, $ 114,700 K
  • Annual Income, $ -56,530 K
  • EBIT $ -161 M
  • EBITDA $ -169 M
  • 60-Month Beta 1.92
  • Price/Sales 7.30
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 138.88% (+13.79%)
  • Historical Volatility 69.43%
  • IV Percentile 66%
  • IV Rank 20.07%
  • IV High 431.75% on 04/10/25
  • IV Low 65.36% on 08/20/25
  • Expected Move (DTE 4) 0.60 (16.53%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 2,074
  • Volume Avg (30-Day) 2,399
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 144,174
  • Open Int (30-Day) 142,939
  • Expected Range 3.01 to 4.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.26
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.65 +39.41%
on 11/17/25
3.80 -2.63%
on 12/11/25
+0.99 (+36.53%)
since 11/14/25
3-Month
2.08 +77.88%
on 10/23/25
3.80 -2.63%
on 12/11/25
+0.52 (+16.35%)
since 09/15/25
52-Week
0.76 +386.84%
on 04/09/25
3.80 -2.63%
on 12/11/25
+2.77 (+297.85%)
since 12/13/24

Most Recent Stories

More News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 3.70 (+2.78%)
Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 3.70 (+2.78%)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 3.70 (+2.78%)
Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 3.70 (+2.78%)
Gossamer Bio: Q3 Earnings Snapshot

Gossamer Bio: Q3 Earnings Snapshot

GOSS : 3.70 (+2.78%)
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

- Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - ...

GOSS : 3.70 (+2.78%)
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed

While the risks remain significant with biotech stocks, the potential rewards could be equally compelling.

ATXS : 12.93 (+0.15%)
AVTX : 18.50 (-0.54%)
GOSS : 3.70 (+2.78%)
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD -

GOSS : 3.70 (+2.78%)
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

- RT234 is an investigational inhaled, as needed (PRN) vardenafil formulation for PAH and PH-ILD, where no on demand treatments exist - - Capital-efficient structure...

GOSS : 3.70 (+2.78%)
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

- One Oral and Four Poster Presentations Highlight Seralutinib’s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease -

GOSS : 3.70 (+2.78%)

Business Summary

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology...

See More

Key Turning Points

3rd Resistance Point 3.97
2nd Resistance Point 3.88
1st Resistance Point 3.74
Last Price 3.70
1st Support Level 3.51
2nd Support Level 3.42
3rd Support Level 3.28

See More

52-Week High 3.80
Last Price 3.70
Fibonacci 61.8% 2.64
Fibonacci 50% 2.28
Fibonacci 38.2% 1.92
52-Week Low 0.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar